August 4, 2017 3SBio obtains ex-China global legal rights to Apexigen’s anti-TNF mAb technology 3SBio Inc http://tadacipla.com ., , a respected China-based biotechnology company focused on researching, developing, marketing and manufacturing biopharmaceutical products, today announced that it offers acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody technology. 3SBio acquired the China rights from Apexigen in 2006 previously. 3SBio's anti-TNF mAb, designated SSS07, provides completed pre-clinical assessment and demonstrated higher potency compared to the best-known available TNF inhibitors, including adalimumab and infliximab, potentially improving treatment options for patients with rheumatoid arthritis and other inflammatory illnesses. Radiologists have the ability to transform ultra high-quality CT patient pictures into 3D solid models using a 3D color printer generally used in architecture, engineering and construction. An edge of 3-D models is that they identify defects that 2-D images do not, which helps radiologists look at a clearer impression of the picture. With increasing regularity, surgeons and other doctors, and patients alike, demand assistance from radiologists to be able to identify complicated morphologies demonstrated on imaging studies. Related StoriesSKYSCAN 1275 provides top quality 3D pictures by automated highly, self optimizing, micro-CTPreclinical Magnetic Particle Imaging: an interview with Professor Jeff Bulte, Johns HopkinsProviding critical protection for patients in the healthcare sector’We are applying a method that has many uses in additional industries to assist surgeons in planning procedures on challenging anatomy and pathology as well as help them talk to patients and their own families.